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Abstract
Purpose of Review The goal of this review is to evaluate the
management options for achondroplasia, the most common
non-lethal skeletal dysplasia. This disease is characterized by
short stature and a variety of complications, some of which
can be quite severe.
Recent Findings Despite several attempts to standardize care,
there is still no widely accepted consensus. This is in part due
to absence of concrete data on the incidence of sudden unex-
plained death in infants with achondroplasia and the best in-
vestigation for ascertaining which individuals could benefit
from foramen magnum decompression surgery.
Summary In this review, we identify the different options of
care and management for the various orthopedic, neurologic,
and respiratory complications. In parallel, several innovative or
drug repositioning therapies are being investigated that would
restore bone growth but may also prevent complications.
Achondroplasia is the most common non-lethal skeletal dys-
plasia. It is characterized by short stature and a variety of com-
plications, some of which can be quite severe. Despite several
attempts to standardize care, there is still no widely accepted
consensus. This is in part due to absence of concrete data on the
incidence of sudden unexplained death in infants with achon-
droplasia and the best investigation for ascertaining which in-
dividuals could benefit from foramen magnum decompression
surgery. In this review, we identify the different options of care
and management for the various orthopedic, neurologic, and
respiratory complications. In parallel, several innovative or
drug repositioning therapies are being investigated that would
restore bone growth but may also prevent complications.
Keywords Achondroplasia . FGFR3 . Treatment .
Biotherapies . Clinical management
Introduction
Achondroplasia is a rare genetic disorder for which no cure is
available. This skeletal dysplasia is the most common form of
short limb dwarfism and was first reported in 1878 [1]. It is
estimated that it affects approximately 250,000 people world-
wide [2•, 3, 4]. The incidence is estimated to be 1 in 10,000 to
30,000 live births per year [5], affecting both males and fe-
males with equal frequency.
Achondroplasia is characterized by prenatal onset of dis-
proportionate short stature [6, 7]. Most affected children and
adults enjoy good general health, but numerous neurological,
orthopedic, and otolaryngologic complications can occur in
this disorder, and an association with sudden infant death
has been reported [8]. The phenotype of achondroplasia is
caused by abnormal endochondral bone development, thus
mainly affecting the growth of the long bones; the vertebrae;
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and several bones in the skull, including the temporal, occip-
ital, sphenoid, and ethmoid bones. The trunk is narrow but of
normal size. Adult height is 131 ± 5.6 cm in males and
124 ± 5.9 cm in females [7, 9].
Achondroplasia is caused by a single point gain-of-
function mutation in the gene coding for fibroblast growth
factor receptor 3 (FGFR3) [10]. It follows an autosomal dom-
inant inheritance; though in 80% of the cases, it is a de novo
mutation [11] associated with increased paternal age, relative
to the general population [12–15]. In 90% of the cases, the
mutation is a Gly380Arg substitution (the most common mu-
tation is 1138G > A transition; a G > C transversion has been
reported in 20% of the cases) [11, 16, 17]. Diagnosis can be
suspected in utero by ultrasound and/or clinical and radiolog-
ical features at birth but should be confirmed by molecular
testing [18]. To help with diagnosis of skeletal dysplasia in-
cluding achondroplasia, non-invasive prenatal testing is being
developed [19]. The penetrance is 100% and the phenotype is
already apparent at birth. Infants with achondroplasia present
characteristic features with macrocephaly with frontal
bossing, midface hypoplasia, and flat nasal bridge. They have
short limbs with predominantly proximal (rhizomelic) short-
ening of the upper limbs [20], joint laxity, and a trident hand
[21]. Intellect is not affected and their lifespan is close to that
of the general population. Children with achondroplasia pres-
ent motor delays notably to acquire standing position and
walking due to muscle hypotonia and ligamentous laxity.
More than 50% of the patients develop an early obesity that
augments the morbidity associated with lumbar lordosis as
well as the severity of sleep apnea or orthopedic complications
such as genua vara.
Achondroplasia is a short stature condition compatible with
good general health and normal life expectancy. Besides the
burden of short stature, health issues may arise from compli-
cations, due to the particular anatomical features of
achondroplasia.
Current Care and Management
Management
Recommendations for management of children with achon-
droplasia have been proposed and updated over time [2•, 22,
23]. However, these guidelines are mainly based on personal
experience of the authors and not on clinical studies.
Treatments aimed at correcting growth have been tried;
growth hormone therapy has no significant effect on adult
stature [24]. Surgical limb lengthening can improve body pro-
portions and final height up to 20 cm but requires multiple
surgeries with high rate of complications and physical burden
[25]. The choice of undergoing limb lengthening depends
largely on cultural and psychosocial factors.
Current management of achondroplasia consists essentially
in prevention and treatment of complications. While there is
agreement on complications and their pathophysiology, there
is no consensus regarding the type and frequency of surveil-
lance because of the lack of prospective controlled clinical
studies. The exact prevalence of each complication is un-
known, in some cases overestimated; it is likely that the over-
all prevalence of complications reaches at least 10%. Figure 1
summarizes the different complications occurring in infants,
toddlers and children, or adults. The most difficult task for
clinicians faced with parents of a newborn with achondropla-
sia is to provide the right information and awareness about the
condition, without overmedicalizing the infant.
Monitoring
Growth and development should be monitored according to
norms for achondroplasia; special charts exist for height,
weight, and occipital frontal circumference (OFC) [6, 22].
OFC is physiologically larger in achondroplasia and should
bemonitored regularly (monthly in the first year of life) in order
to detect any unusual acceleration as a possible sign of hydro-
cephaly, a rare but potentially severe complication. Gross motor
skills are often delayed [26, 27], probably due to the
anatomical-biomechanical features of this condition with large
head, short limbs, and joint hypermobility [28]. Fine motor and
feeding skills are usually not delayed and language delay is
variable. Overall, most children reach all normal developmental
milestones and have no neurological or intellectual impairment;
access to physiotherapy, occupational therapy, and language
therapists with experience in achondroplasia may significantly
improve timing of autonomy [26].
Complications
The most frequent complications observed in achondroplasia
children are ENT issues: upper airways are anatomically smaller
in achondroplasia and as a consequence, middle ear effusions
and infections occur frequently, sometimes leading to conductive
hearing loss and subsequent speech delay; tonsillectomy and
adenoidectomy may be necessary to reduce airway obstruction,
especially in the case of obstructive sleep apnea [29]. Obstructive
sleep apnea is reported in >50% of patients [30], possibly be-
cause of a combination of small airways, hypotonia, andmidface
hypoplasia. Clinical surveillance by an ENT specialist with ex-
perience in achondroplasia is recommended particularly between
1 and 4 years of age. Pulmonary complications are rare, but
restrictive pulmonary disease may occur, particularly in children
living at high altitude [23].
For infants with achondroplasia, their parents, and their
doctors, the most frightful complication is sudden infant
death. It has been reported to occur in up to 7.5% of achon-
droplasia infants <1 year [31], but its incidence is probably
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overestimated; a more recent study reports a sixfold increase
in infant mortality in achondroplasia compared to the general
population [32]. It is thought to be due to spinal cord com-
pression at the cervicomedullary junction secondary to a ste-
notic foramen magnum. Sleep-disordered breathing may con-
tribute to increased mortality; however, no clear correlation
has been found between central sleep apnea and foramenmag-
num stenosis. Always in relationship with foramen magnum
stenosis, ventriculomegaly is frequent in achondroplasia in-
fants, due to disturbed CSF circulation at the foramen mag-
num, but true hydrocephaly as a cause of acute intracranial
hypertension seems to be much rarer [33, 34]. Some centers
perform serial MRI, electrophysiological and sleep studies
starting from birth and during the first year of life. However,
this surveillance is not without drawbacks: brain and spinal
MRI require general anesthesia and somato-sensory evoked
potentials may not show changes in presymptomatic phase. In
addition, all babies with achondroplasia have a narrow fora-
menmagnum (Fig. 2a), which usually improves with age [35].
No specific marker has been identified so far to distinguish
which asymptomatic patients need prophylactic decompres-
sion of the foramen magnum, and there is no evidence-based
strategy; it is currently recommended that only symptomatic
infants (with some clinical neurological signs and/or patho-
logic polysomnography) undergo brain imaging [36••].
Careful clinical surveillance by a multidisciplinary team ex-
perienced in achondroplasia may prove to be as sensible as
investigations in detecting critical brainstem compression: in-
creased generalized hypotonia, changes in osteotendinous re-
flexes (hyperreflexia, clonus, asymmetry), and subtle signs of
intracranial hypertension (prominent fontanella, rapid increase
of OFC) should be monitored, preferably by the same
professional, every 2 months [36••]; family doctors should
be informed about signs and symptoms to be surveyed in
between the visits at the specialized center. Some centers pro-
pose sleep studies and even matrasses with detectors of sleep
apnea; the utility of these measures has not been proven and
the occurrence of sleep apnea appears to be only poorly cor-
related with foramen magnum stenosis [37, 38].
Orthopedic complications are possible at all ages. In the
first year of life, some degree of kyphosis is always present
at the low thoracic and lumbar region (Fig. 2b); it persists until
acquirement of standing position, when it reverses to a
hyperlordosis. It is recommended to avoid carrying the baby
in the first months of life in baby wraps, which do not support
the back and favor a kyphotic posture. Later on, the sitting
position should not be imposed before the baby has enough
muscle strength to sit autonomously. Bracing is not needed in
all cases but may be useful to contain kyphosis when the baby
is in a sitting position (meals, landau walks). Some children
are particularly hypermobile and very delayed in sitting au-
tonomously and standing. In these cases, to avoid a fixed
kyphosis, appropriate bracing and/or adapted seats supporting
the dorsolumbar spine should be provided. Hypermobility of
the knee may also lead to instability and delayed walking but
does not usually cause deformity or pain in the first years of
life. Physiotherapy may be helpful in gaining correct postures
and motoric strategies before free walking is achieved.
In toddlers and children, angular deformities of the lower
limbs may develop with walking. Referral to orthopedic sur-
geons is reserved for patients with a specific problem, such as
marked genua vara. External rotation of the hips is frequent and
benign and usually resolves when the child starts walking.
Obesity is an additional risk factor for orthopedic deformities




and joint complications. Starting from when the child has
achieved a height of 75 cm, weight/height ratio should be mon-
itored [6] and, if necessary, nutritional counseling be offered.
In adults, the main orthopedic complication is lumbar spi-
nal stenosis between L1 and L4, due to a narrow spinal canal
and shorter vertebral arches. It can cause back pain and pe-
ripheral nerve compression. Spinal stenosis affects approxi-
mately 10% of adults with achondroplasia, and decompres-
sion surgery may be necessary in young adults [39].
Daily Living
Living with achondroplasia is associated with all the practical
problems of short-limbed short stature in respect to
architectural barriers (access to toilets, public desks, automats,
public transports, etc). In addition, short arms and limited
elbow extension significantly limit autonomy in personal care
(dressing, personal hygiene, etc.). Occupational therapy, par-
ticularly from school age on, is helpful in finding strategies to
overcome these limitations.
Social functioning is normal for most children with achon-
droplasia. The psychosocial burden of achondroplasia de-
pends on several personal, familial, ethnic, and cultural fac-
tors. Some families will have a strong perception of handicap
for a child with achondroplasia, while others will not perceive
the condition as a problem. Educational guidance for parents
of children with achondroplasia should be offered at the
achondroplasiamultidisciplinary clinic, to prevent overprotec-
tion, limited autonomy, and excessive anxiety. Psychological
support should be offered to help acceptance of the condition,
first to parents of affected infants in order to promote estab-
lishment of appropriate affective links and later to children
and teenagers facing frustration and rebellion toward diversity.
Support groups may also be helpful for patients and families
to share experiences and reinforce positive individual
resources.
Investigational Therapies
Current care for achondroplasia manages the symptoms and
alleviates the consequences of complications. To be effective,
a new treatment approach must consider achondroplasia as a
complex disease, correcting the short stature and preventing
complications. Understanding the pathophysiology of the dis-
ease is essential to achieve this and correct the growth of all
bones affected by the disease. As stated above, achondroplasia
is caused by a mutation in the FGFR3 gene resulting in ab-
normal endochondral ossification. FGFR3 signaling negative-
ly regulates endochondral bone growth [40] by inhibiting the
rate of chondrocyte proliferation and the initiation of chondro-
cyte hypertrophy [41] through activation of the Stat1 and
MAPK pathways [42, 43]. In achondroplasia, the G380R mu-
tation, located in the transmembrane domain of FGFR3, ex-
tends the signaling cascade resulting in prolonged bone
growth inhibition (Fig. 3a). The dimerization and activation
of mutant FGFR3 is ligand-dependent [44–46] and stabilizes
the ligand/receptor complex by decreasing its internalization
[46–48].
Several approaches have been developed to target FGFR3
within the cartilage either by blocking its activation, inhibiting
downstream signaling, or increasing its turnover [49•]. Among
them, we have recently evaluated the use of a FGFR3 decoy
receptor (sFGFR3) to avoid the FGF ligand from binding to
the receptor, thus preventing activation of the intracellular
signaling directly downstream of mutant FGFR3 resulting in
bone growth activation (Fig. 3b) [45]. The sFGFR3 decoy
lacks the transmembrane domain and is thus secreted from
Fig. 2 aMRI image of a four and a half year old boy showing a narrow
foramen magnum. This finding is seen in almost all children with
achondroplasia and is not by itself an indication to perform
neurosurgery. b X-ray showing the typical configuration of the lumbar
spine in achondroplasia with shortening in the AP diameter and
scalloping if the posterior endplates. More significant shortening of the
first lumbar vertebra is also a risk factor for developing a fixed kyphosis
and would be an indication for treatment by bracing
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the cells, unable to activate the signaling cascade [50].
sFGFR3 was administered subcutaneously for 3 weeks to
mice carrying the G380R mutation (Fgfr3ach/+ mice) and
was able to penetrate the growth plate cartilage. At a dose of
2.5 mg/kg twice weekly from age 3 days to 3 weeks, sFGFR3
treatment was effective at restoring normal body, tail, and long
bone lengths in treated Fgfr3ach/+ mice. Interestingly, follow-
ing treatment, significant reduction in respiratory failure and
spinal compression were observed. Treated Fgfr3ach/+ mice
also showed normal rib cage development and decreased ver-
tebrae and skull deformities. No obvious toxicity was ob-
served and treatment did not affect reproduction. One unex-
pected advantageous side effect was the increase in pelvis size
in primiparous-treated Fgfr3ach/+ females resulting in normal
size litters. If this translates into humans, this would be a
significant advantage, as during delivery achondroplasia pa-
tients must undergo C-section due to small pelvis size. The
decoy approach shows promise as a potential treatment for
achondroplasia restoring not only the stature but also
preventing most of the complications due to the characteristic
features of achondroplasia.
A 12 amino acid peptide (called P3) binding with high
affinity to the extracellular domain of FGFR3 has been eval-
uated in mice with thanatophoric dysplasia type II (TDII), a
more severe form of FGFR3-related skeletal dysplasia [51].
In vitro, P3 treatment restored chondrocyte proliferation and
differentiation by decreasing the MAPK signaling cascade.
When administered to neonatal TDII pups, animals survived
and treatment partially rescued endochondrial bone growth.
Interestingly, this treatment had positive effects on long bones
but also rescued neonatal lethality potentially preventing some
of the complications caused by spinal and skull deformities.
In 2014, Yamashita et al. evaluated the use of statin to
rescue bone growth in achondroplasia and thanatophoric dys-
plasia type I (TDI) [52••]. The rationale for repositioning this
pleiotropic drug is that it appears to stimulate bone growth
through anabolic effects on chondrocytes [53–55]. While the
exact mechanism of action is unknown, it is suspected that
statin treatment may accelerate FGFR3 degradation on
chondrocytes [52••, 56]. In this study, the authors first develop
a cell-based system using induced pluripotent stem cells
(iPSCs) generated from dermal fibroblasts of achondroplasia
and TDI patients. Following reprogramming of these cells and
differentiation into chondrocytes, this cell culture assay dis-
plays similarities with patient chondrocytes with decreased
chondrogenic potential that was rescued by lovastatin treat-
ment. In vivo, daily intraperitoneal injections of 1 mg/kg
rosuvastatin from 3 to 6 weeks of age partially restored limb
and skull lengths of Fgfr3ach/+ mice showing potential thera-
peutic effects of statins. However, while there are abundant
data on the use of statin in humans, little is known about safety
in children.
Another repositioning approach has been evaluated recent-
ly using meclozine, an over-the-counter antihistamine drug
used for motion sickness. The authors initially showed
in vitro effects of meclozine on chondrocyte proliferation
and differentiation [57]. Transgenic Fgfr3ach/+ mice orally
treated with meclozine showed an improvement in the dwarf
phenotype with an increase in bone length [58]. The specific
mechanism remains unknown, and the safety profile of chron-
ic administration of meclozine in children has yet to be
evaluated.
Small molecule approaches targeting tyrosine kinase do-
mains have been explored for over a decade in anticancer
therapies [59]. Their application to skeletal dysplasia appears
promising at rescuing the achondroplasia phenotype in vitro
and in explant culture systems [60–62]. However, the rele-
vance of their in vivo application is unclear because of their
absence of selectivity for FGFR3 [60], potentially inhibiting
the activities of other FGFR and other tyrosine kinases, induc-
ing multiorgan toxicity [62]. Additional development is need-
ed to further improve the specificity.
Biomarin Pharmaceuticals is currently conducting a phase
2 clinical trial on children with achondroplasia using
vosoritide, a C-type natriuretic peptide (CNP) analog [49•].
The CNP approach has been evaluated for nearly two decades
now and acts indirectly on FGFR3 signaling though the
MAPK signaling pathway not the Stat1 cascade [63, 64].
Fig. 3 Schematic representation
of FGFR3-mediated inhibition of
bone growth in achondroplasia
(a) and of the sFGFR3 decoy
strategy (b)
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Skeletal phenotype was rescued in double transgenic mice
overexpressing both the mutant FGFR3 receptor and CNP in
growth plate chondrocytes [65]. Following chronic infusion of
CNP, mice with achondroplasia had longer long bones but
also larger foramen magnum, suggesting a potential treatment
effect on the occurrence of the complications [66, 67].
Biomarin is now using an analog with a prolonged half-life
that proved to be effective at increasing bone length in mice
and growth plate width in monkey [68]. The initial phase 2
results are very encouraging demonstrating a favorable safety
profile and an increase in 50% of the annualized growth ve-
locity following daily subcutaneous administration of 15 g/kg
vosoritide for 12 months compared to the pretreatment growth
velocity [69]. The body proportions, calculated as the ratio of
upper body length to leg length, which is higher in children
with achondroplasia, were not improved by vosoritide treat-
ment. In a prospective observational study, Olney et al. recent-
ly showed that CNP plasma levels are elevated in achondro-
plasia patients suggesting that these patients may have a nat-
ural resistance to CNP [70]. Further investigation would be
necessary to clarify this as it could interfere with long-term
treatment efficacy of vosoritide.
Conclusion
In spite of being the most common form of skeletal dysplasia,
there exists no clear consensus on care and management for
children and adults with achondroplasia. Developing a routine
healthcare is of high importance and would greatly benefit
some patients who tend to be overmedicalized or are far re-
moved from specialized centers. A natural history multicenter
study has been very recently started to increase the “collabora-
tion among researchers to gather similarly affected patients to
answer common clinical research questions”. This type of ini-
tiative is essential to improve care and management of these
patients. In parallel, the development of biotherapies directly
targeting FGFR3 could resolve these issues. However, in addi-
tion to rescuing skeletal growth, these therapies should address
all of the other (or at least some) clinical aspects of achondro-
plasia thus preventing the development of complications.
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